Bristol Myers Squibb, Johnson & Johnson halt major heart-drug trial after disappointing results

FDA approves Alembic's Ticagrelor Tablets, 60 mg

Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients

Alembic receives USFDA final approval for Ticagrelor Tablets, 90 mg and tentative approval for Ticagrelor Tablets, 60 mg

Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,

Jiangsu Vcare files NDA for Vicagrel Capsules with USFDA

Venus Remedies expands global presence with marketing authorisation for enoxaparin from Azerbaijan

The company makes its maiden entry into Azerbaijan’s pharmaceutical market

Unichem receives ANDA approval for Prasugrel Tablets

Prasugrel tablets are indicated to reduce the rate of thrombotic CV events

Lupin Digital Health reveals results of digital therapeutics study with ACS patients

The one-year-long study was aimed to evaluate the efficacy of LDH's digital therapeutics platform